Alpha Teknova assumed with a Buy at BTIG

BTIG assumed coverage of Alpha Teknova with a Buy rating and $6.00 price target. The company is a leading provider of customized reagents which are sold to over 3,000 customers across the life sciences industry, including in molecular diagnostics, therapeutics, and vaccines, having recently undergone a strategic pivot from offering off-the-shelf products to driving greater focus on producing higher-value, made-to-order, customized reagents, the analyst tells investors in a research note. Alpha Teknova has only recently made investments in commercial teams and next-generation lab automation and should now be able to reap the fruit of its investments, the firm adds.